

NOVARTIS AG
Form POSASR
November 20, 2015

Registration No. 333-207004

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Post-Effective Amendment No. 1

to

Form F-3

REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

Novartis AG

(Exact name of Registrant as specified in its charter)

Novartis Inc.

(Translation of Registrant's name into English)

Switzerland

(State or other jurisdiction of incorporation or organization)

Not Applicable

(I.R.S. Employer Identification No.)

Edgar Filing: NOVARTIS AG - Form POSASR

Lichtstrasse 35

4056 Basel, Switzerland

+41 61 324 1111

(Address and telephone number of Registrant's principal executive offices)

Novartis Capital Corporation

(Exact name of Registrant as specified in its charter)

Not Applicable

(Translation of Registrant's name into English)

Delaware

(State or other jurisdiction of incorporation or organization)

26-3086456

(I.R.S. Employer Identification No.)

**230 Park Avenue, 21st Floor
New York, New York 10169**

+ 1 212 307 1122

(Address and telephone number of Registrant's principal executive offices)

Novartis Securities Investment Ltd.

(Exact name of Registrant as specified in its charter)

Not Applicable

(Translation of Registrant's name into English)

Bermuda

(State or other jurisdiction of incorporation or organization)

Not Applicable

(I.R.S. Employer Identification No.)

**131 Front Street
Hamilton, HM12, Bermuda**

+1 441 296 8025

(Address and telephone number of Registrant's principal executive offices)

Dr. Felix R. Ehrat

Dr. Christian Rehm

Novartis AG

Lichtstrasse 35

CH-4056 Basel

Switzerland

+41 61 324 1111

(Name, address and telephone number of agent for service)

Copies of all communications to:

**Bernd Bohr
Mayer Brown International LLP
201 Bishopsgate
London EC2M 3AF
+44 20 3130 3640**

**Stuart K. Fleischmann
Shearman & Sterling LLP
599 Lexington Ave
New York, NY 10022
+1 212 848 7527**

Edgar Filing: NOVARTIS AG - Form POSASR

Approximate date of commencement of proposed sale to the public: **From time to time after this Registration Statement becomes effective.**

If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box. ☐

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box. ☒

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a registration statement pursuant to General Instruction I.C. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. ☒

If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.C. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box. ☐

Explanatory Note

The purpose of this Post-Effective Amendment No. 1 to the registration statement is to file certain exhibits to the registration statement.

PART II

INFORMATION NOT REQUIRED IN PROSPECTUS

Item 9. Exhibits

Exhibit Number	Description
1.1	Form of Underwriting Agreement (1)
4.1	Indenture, dated February 10, 2009 among Novartis Capital Corporation, Novartis Securities Investment Ltd. and Novartis Finance S.A., as issuers, Novartis AG, as guarantor, and HSBC Bank USA, National Association, as trustee (2)
4.2	Form of Guaranteed Debt Security (3)
4.3	Form of Guaranteed Debt Security for 3.000% Notes due 2025
4.4	Form of Guaranteed Debt Security for 4.000% Notes due 2045
4.5	Officers' Certificate of Novartis Capital Corporation
5.1	Opinion of Mayer Brown International LLP, special U.S. counsel to Novartis AG, Novartis Capital Corporation and Novartis Securities Investment Ltd. (4)
5.2	Opinion of Bär & Karrer AG, special Swiss counsel to Novartis AG (5)
5.3	Opinion of Appleby, special Bermuda counsel to Novartis Securities Investment Ltd. (6)
5.4	Opinion of Mayer Brown International LLP, special U.S. counsel to Novartis AG and Novartis Capital Corporation
5.5	Opinion of Bär & Karrer AG, special Swiss counsel to Novartis AG
12.1	Computation of Ratio of Earnings to Fixed Charges (7)
12.2	Computation of Ratio of Earnings to Fixed Charges (8)
23.1	Consent of Mayer Brown International LLP (included in Exhibits 5.1 and 5.4)
23.2	Consent of Bär & Karrer AG (included in Exhibits 5.2 and 5.5)
23.3	Consent of Appleby (included in Exhibit 5.3)
23.4	Consent of PricewaterhouseCoopers AG (9)
24.1	Powers of Attorney (10)
25.1	Statement of Eligibility under the Trust Indenture Act of 1939, as amended, of HSBC Bank USA, National Association (11)

(1) Incorporated by reference to Exhibit 1.1 to Form F-3 (file no. 333-207004) filed with the SEC on September 18, 2015

(2) Incorporated by reference to Exhibit 4.1 to Form F-3 (file no. 333-207004) filed with the SEC on September 18, 2015

(3) Incorporated by reference to Exhibit 4.2 to Form F-3 (file no. 333-207004) filed with the SEC on September 18, 2015

(4) Incorporated by reference to Exhibit 5.1 to Form F-3 (file no. 333-207004) filed with the SEC on September 18, 2015

Edgar Filing: NOVARTIS AG - Form POSASR

- (5) Incorporated by reference to Exhibit 5.2 to Form F-3 (file no. 333-207004) filed with the SEC on September 18, 2015
- (6) Incorporated by reference to Exhibit 5.3 to Form F-3 (file no. 333-207004) filed with the SEC on September 18, 2015
- (7) Incorporated by reference to Exhibit 12.1 to Form F-3 (file no. 333-207004) filed with the SEC on September 18, 2015
- (8) Incorporated by reference to Exhibit 12.2 of the Report on Form 6-K furnished to the SEC on November [17], 2015 with a statement of computation of the ratio of earnings to fixed charges
- (9) Incorporated by reference to Exhibit 23.4 to Form F-3 (file no. 333-207004) filed with the SEC on September 18, 2015
- (10) Incorporated by reference to the signature pages of Form F-3 (file no. 333-207004) filed with the SEC on September 18, 2015
- (11) Incorporated by reference to Exhibit 25.1 to Form F-3 (file no. 333-207004) filed with the SEC on September 18, 2015

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the registrant, Novartis AG, certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form F-3 and has duly caused this Post-Effective Amendment No. 1 to the registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Basel, on the 20th day of November, 2015.

Novartis AG

By: /s/ DANIEL WEISS
 Name: Daniel Weiss
 Title: Authorized Signatory

By: /s/ DR. CHRISTIAN REHM
 Name: Dr. Christian Rehm
 Title: Authorized Signatory

Pursuant to the requirements of the Securities Act of 1933, this Post-Effective Amendment No. 1 to the registration statement has been signed by the following persons in the capacities and on the dates indicated.

Signature	Title	Date
* Joseph Jimenez	Chief Executive Officer (principal executive officer)	November 20, 2015
* Harry Kirsch	Chief Financial Officer (principal financial and accounting officer)	November 20, 2015
* Dr. Joerg Reinhardt	Chairman of the Board of Directors	November 20, 2015
* Dr. Enrico Vanni	Vice Chairman of the Board of Directors	November 20, 2015
* Dr. Nancy C. Andrews	Director	November 20, 2015
* Dr. Dimitri Azar	Director	November 20, 2015
* Dr. Verena A. Briner	Director	November 20, 2015

Post-Effective Amendment No.1 to Registration Statement

Edgar Filing: NOVARTIS AG - Form POSASR

Signature	Title	Date
* Dr. Srikant Datar	Director	November 20, 2015
* Ann Fudge	Director	November 20, 2015
* Dr. Pierre Landolt	Director	November 20, 2015
* Dr. Andreas von Planta	Director	November 20, 2015
* Dr. Charles L. Sawyers	Director	November 20, 2015
* William T. Winters	Director	November 20, 2015
* Barry Rosenfeld	Authorized U.S. Representative	November 20, 2015

Post-Effective Amendment No.1 to Registration Statement

Edgar Filing: NOVARTIS AG - Form POSASR

Pursuant to the requirements of the Securities Act of 1933, the registrant, Novartis Capital Corporation, certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form F-3 and has duly caused this Post-Effective Amendment No. 1 to the registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Basel, on the 20th day of November, 2015.

Novartis Capital Corporation

By:

*

Name:

Craig Osten

Title:

Director and President (principal executive officer and principal financial and accounting officer)

Pursuant to the requirements of the Securities Act of 1933, this Post-Effective Amendment No. 1 to the registration statement has been signed by the following persons in the capacities and on the dates indicated.

Signature	Title	Date
* Felix Senn	Chairman of the Board of Directors	November 20, 2015
* Craig Osten	Director and President (principal executive officer and principal financial and accounting officer)	November 20, 2015

Post-Effective Amendment No.1 to Registration Statement

Edgar Filing: NOVARTIS AG - Form POSASR

Pursuant to the requirements of the Securities Act of 1933, the registrant, Novartis Securities Investment Ltd., certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form F-3 and has duly caused this Post-Effective Amendment No. 1 to the registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Basel, on the 20th day of November, 2015.

Novartis Securities Investment Ltd.

By:

*

Name:

Simon Zivi

Title:

Chairman of the Board of Directors (principal executive officer and principal financial and accounting officer)

By:

*

Name:

Michael L. Jones

Title:

Deputy Chairman of the Board of Directors and Secretary

Pursuant to the requirements of the Securities Act of 1933, this Post-Effective Amendment No. 1 to the registration statement has been signed by the following persons in the capacities and on the dates indicated.

Signature	Title	Date
* Simon Zivi	Chairman of the Board of Directors (principal executive officer and principal financial and accounting officer)	November 20, 2015
* Michael L. Jones	Deputy Chairman of the Board of Directors and Secretary	November 20, 2015
* Felix Eichhorn	Director	November 20, 2015
* Timothy Faries	Director	November 20, 2015
* Alison Dyer-Fagundo	Alternate Director	November 20, 2015
* Tonesan Amissah	Alternate Director	November 20, 2015
* Barry Rosenfeld	Authorized U.S. Representative	November 20, 2015

Post-Effective Amendment No.1 to Registration Statement

*By his signature below, each of the undersigned, pursuant to a duly authorized power of attorney filed with the Securities and Exchange Commission, have signed this Post-Effective Amendment No. 1 to the registration statement on behalf of the person indicated.

/s/ DANIEL WEISS
Daniel Weiss

/s/ DR. CHRISTIAN REHM
Dr. Christian Rehm

Post-Effective Amendment No.1 to Registration Statement

II-7

EXHIBIT INDEX

Exhibit Number	Description
1.1	Form of Underwriting Agreement (1)
4.1	Indenture, dated February 10, 2009 among Novartis Capital Corporation, Novartis Securities Investment Ltd. and Novartis Finance S.A., as issuers, Novartis AG, as guarantor, and HSBC Bank USA, National Association, as trustee (2)
4.2	Form of Guaranteed Debt Security (3)
4.3	Form of Guaranteed Debt Security for 3.000% Notes due 2025
4.4	Form of Guaranteed Debt Security for 4.000% Notes due 2045
4.5	Officer's Certificate of Novartis Capital Corporation
5.1	Opinion of Mayer Brown International LLP, special U.S. counsel to Novartis AG, Novartis Capital Corporation and Novartis Securities Investment Ltd. (4)
5.2	Opinion of Bär & Karrer AG, special Swiss counsel to Novartis AG (5)
5.3	Opinion of Appleby, special Bermuda counsel to Novartis Securities Investment Ltd. (6)
5.4	Opinion of Mayer Brown International LLP, special U.S. counsel to Novartis AG and Novartis Capital Corporation
5.5	Opinion of Bär & Karrer AG, special Swiss counsel to Novartis AG
12.1	Computation of Ratio of Earnings to Fixed Charges (7)
12.2	Computation of Ratio of Earnings to Fixed Charges (8)
23.1	Consent of Mayer Brown International LLP (included in Exhibits 5.1 and 5.4)
23.2	Consent of Bär & Karrer AG (included in Exhibits 5.2 and 5.5)
23.3	Consent of Appleby (included in Exhibit 5.3)
23.4	Consent of PricewaterhouseCoopers AG (9)
24.1	Powers of Attorney (10)
25.1	Statement of Eligibility under the Trust Indenture Act of 1939, as amended, of HSBC Bank USA, National Association (11)

-
- (1) Incorporated by reference to Exhibit 1.1 to Form F-3 (file no. 333-207004) filed with the SEC on September 18, 2015
 - (2) Incorporated by reference to Exhibit 4.1 to Form F-3 (file no. 333-207004) filed with the SEC on September 18, 2015
 - (3) Incorporated by reference to Exhibit 4.2 to Form F-3 (file no. 333-207004) filed with the SEC on September 18, 2015
 - (4) Incorporated by reference to Exhibit 5.1 to Form F-3 (file no. 333-207004) filed with the SEC on September 18, 2015
 - (5) Incorporated by reference to Exhibit 5.2 to Form F-3 (file no. 333-207004) filed with the SEC on September 18, 2015

- (6) Incorporated by reference to Exhibit 5.3 to Form F-3 (file no. 333-207004) filed with the SEC on September 18, 2015
- (7) Incorporated by reference to Exhibit 12.1 to Form F-3 (file no. 333-207004) filed with the SEC on September 18, 2015
- (8) Incorporated by reference to Exhibit 12.2 of the Report on Form 6-K furnished to the SEC on November [17], 2015 with a statement of computation of the ratio of earnings to fixed charges
- (9) Incorporated by reference to Exhibit 23.4 to Form F-3 (file no. 333-207004) filed with the SEC on September 18, 2015
- (10) Incorporated by reference to the signature pages of Form F-3 (file no. 333-207004) filed with the SEC on September 18, 2015
- (11) Incorporated by reference to Exhibit 25.1 to Form F-3 (file no. 333-207004) filed with the SEC on September 18, 2015